Core Insights - Scienture Holdings, Inc. has commenced commercial sales of Arbli (losartan potassium) Oral Suspension, 10 mg/mL, which is the first FDA-approved ready-to-use oral suspension for hypertension patients aged 6 and above [1][5] - Arbli is the only liquid formulation of losartan available that does not require compounding, providing benefits such as reduced dosing volume and a long shelf life at room temperature [2] Market Overview - The U.S. losartan market is valued at approximately $256 million in annual sales, with over 71 million prescriptions written each year [2] - Scienture has established agreements with pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs) to enhance commercial coverage and formulary access for Arbli [3] Distribution Strategy - The company has formalized multiple GPO agreements, allowing Arbli to access over 2,500 healthcare institutions across the U.S., including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers [3][4] - This distribution strategy aims to penetrate an estimated 20% of the U.S. institutional market [4]
EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients